Precigen's (PGEN) "Market Outperform" Rating Reaffirmed at JMP Securities

Precigen (NASDAQ:PGEN - Get Free Report)'s stock had its "market outperform" rating reaffirmed by stock analysts at JMP Securities in a research note issued on Tuesday,Benzinga reports. They currently have a $5.00 price objective on the biotechnology company's stock. JMP Securities' price objective points to a potential upside of 360.83% from the stock's current price.

Separately, HC Wainwright restated a "buy" rating and set a $4.00 price target on shares of Precigen in a research note on Friday, November 15th. Two investment analysts have rated the stock with a sell rating and four have given a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus price target of $6.33.

Precigen Stock Performance

NASDAQ PGEN traded up $0.02 during trading on Tuesday, hitting $1.09. 688,980 shares of the company's stock traded hands, compared to its average volume of 2,629,323. The stock has a market capitalization of $317.76 million, a price-to-earnings ratio of -1.97 and a beta of 1.65. Precigen has a 12-month low of $0.65 and a 12-month high of $1.93. The business has a 50 day moving average of $0.90 and a 200-day moving average of $1.08.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Traphagen Investment Advisors LLC purchased a new stake in shares of Precigen in the third quarter worth $29,000. Stifel Financial Corp increased its stake in Precigen by 94.9% in the 3rd quarter. Stifel Financial Corp now owns 32,200 shares of the biotechnology company's stock worth $30,000 after acquiring an additional 15,680 shares during the last quarter. SG Americas Securities LLC raised its holdings in shares of Precigen by 44.2% in the 3rd quarter. SG Americas Securities LLC now owns 45,063 shares of the biotechnology company's stock valued at $43,000 after acquiring an additional 13,823 shares in the last quarter. AQR Capital Management LLC boosted its position in shares of Precigen by 56.7% during the 2nd quarter. AQR Capital Management LLC now owns 50,002 shares of the biotechnology company's stock valued at $79,000 after acquiring an additional 18,097 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. grew its holdings in shares of Precigen by 86.6% during the third quarter. China Universal Asset Management Co. Ltd. now owns 55,337 shares of the biotechnology company's stock worth $52,000 after purchasing an additional 25,681 shares in the last quarter. Hedge funds and other institutional investors own 33.51% of the company's stock.

Precigen Company Profile

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.